Efficacy and safety profile of roflumilast in a real-world experience
JOURNAL OF THORACIC DISEASE, cilt.11, sa.4, ss.1100-1105, 2019 (SCI-Expanded)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 11 Sayı: 4
- Basım Tarihi: 2019
- Doi Numarası: 10.21037/jtd.2019.04.49
- Dergi Adı: JOURNAL OF THORACIC DISEASE
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.1100-1105
- Anahtar Kelimeler: Chronic obstructive pulmonary disease (COPD), roflumilast, efficacy, safety, OBSTRUCTIVE PULMONARY-DISEASE, COPD
- Akdeniz Üniversitesi Adresli: Evet
Özet
Background: Roflumilast is the only phosphodiesterase enzyme 4 inhibitor approved in the treatment of chronic obstructive pulmonary disease (COPD) patients with chronic cough and sputum and a history of exacerbations. Real-world studies about the use of roflumilast are limited. Our aim was to assess the efficacy, safety and tolerability of roflumilast in the treatment of stable COPD, in a real-world setting.